Weekly News Round-up – 27/3/20
3 years ago
By Josh Neil
It’s that time again! We’ve got all the news you wanted this week, as long as you wanted to read about nothing except COVID-19, constantly. But to cheer things up, we’ve left out the story that we’re heading towards a worse financial impact than the 2008 crisis. Welcome back to:
The Round-up Coronavirus Special
(Part 2 of 30,000)
PHARMA GIANTS COLLABORATE ON COVID-19 TREATMENT – Several big pharma companies, including Novartis and J&J, are collaborating to develop COVID-19 vaccines. The 15 companies will share data and proprietary molecule libraries, following a recent conference call.
GILEAD ASKS FDA TO RESCIND ORPHAN DRUG STATUS OF REMDESIVIR AFTER CRITICISM – Gilead has requested that the FDA rescind the orphan drug status recently given to Remdesivir, a potential treatment for COVID-19. Gilead made the suggestion after public backlash that this could incentivise price-raises. Small-scale Chinese trials recently found the drug was efficacious in coronavirus patients. Demand for the drug is so high that last Saturday Gilead announced it will halt emergency access to it, due to “overwhelming demand”.
NICE UPDATE COVID-19 GUIDELINES – NICE has published the first of three guidelines on managing patients with and without COVID-19. These cover critical care, kidney dialysis and treatment of patients receiving systemic anticancer treatments. Among other things, the guidelines set out discussions with patients and families about risks and benefits of treatments, and making decisions on the basis of medical benefit.
In other news:
R&D
Sanofi and Translate Bio working together on novel COVID-19 mRNA vaccine
Clinical Trials
UK to begin clinical testing of COVID-19 next month
Manufacturing
That’s all for now. See you next week!
Joshua Neil, Editor
Proventa International
To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Clinical Operations, Supply Chain & Pharmacovigilance Strategy Meeting 2020.
RNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years agoRNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years ago
Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years ago
Intrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets
Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...
2 years agoIntrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets
Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...
2 years ago